Alzheimer's Disease: Epidemiology Forecast to 2028

Summary

Alzheimer’s Disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly. AD is characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities including thinking, language, and learning capacity (National Institute on Aging, 2019). AD is the most common type of dementia (Centers for Disease Control and Prevention, 2019).

The publisher epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for AD was based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV) and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of AD in the 8MM, segmented by age, sex, and severity.

The following data describes epidemiology of AD. In the 8MM, the publisher epidemiologists forecast an increase in the total prevalent cases of AD from 32,753,241 cases in 2018 to 44,473,527 cases in 2028 at an AGR of 3.58% during the forecast period. In the 8MM, the diagnosed prevalent cases of AD will increase from 9,120,848 cases in 2018 to 12,348,971 cases in 2028 at an AGR of 3.54% during the forecast period. AD is more common in older adults. These trends are reflected in the publisher's forecast for the total prevalent cases, and diagnosed prevalent cases for the 8MM.

Scope

The Alzheimer’s disease (AD) Epidemiology Report provides an overview of the risk factors and global trends of AD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
The report includes a 10-year epidemiological forecast for the prevalent cases of AD (total and diagnosed) segmented by sex, age (ages ≥60 years), and severity in these markets. Additionally, this report provides a 10-year epidemiological forecast for the prevalent cases of mild cognitive impairment (MCI) (total and diagnosed) segmented by sex and age (ages ≥60 years) in these markets.
The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The Alzheimer’s Disease Epidemiology series will allow you to -

Develop business strategies by understanding the trends shaping and driving the global AD market.
Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
Understand magnitude of AD population by severity at diagnosis.

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Alzheimer’s Disease: Executive Summary

2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Epidemiology

3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for AD (2018-2028)
3.5.1 Total Prevalent Cases of AD
3.5.2 Sex-Specific Total Prevalent Cases of AD
3.5.3 Age-Specific Total Prevalent Cases of AD
3.5.4 Total Prevalent Cases of AD by Severity
3.5.5 Diagnosed Prevalent Cases of AD
3.5.6 Sex-Specific Diagnosed Prevalent Cases of AD
3.5.7 Age-Specific Diagnosed Prevalent Cases of AD
3.5.8 Diagnosed Prevalent Cases of AD by Severity
3.5.9 Total Prevalent Cases of Mild Cognitive Impairment
3.5.10 Sex-Specific Total Prevalent Cases of Mild Cognitive Impairment
3.5.11 Age-Specific Total Prevalent Cases of Mild Cognitive Impairment
3.5.12 Diagnosed Prevalent Cases of Mild Cognitive Impairment
3.5.13 Sex-Specific Diagnosed Prevalent Cases of Mild Cognitive Impairment
3.5.14 Age-Specific Diagnosed Prevalent Cases of Mild Cognitive Impairment
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography
4.2 Primary Research - KOLs Interviewed for this Report
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About the Publisher
4.5 Contact
4.6 Disclaimer

List of Tables

Table 1: Summary of Newly Added Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for AD

List of Figures

Figure 1: 8MM, Total Prevalent Cases of AD, Men and Women, Ages =60 Years, 2018 and 2028
Figure 2: 8MM, Diagnosed Prevalent Cases of AD, Men and Women, Ages =60 Years, 2018 and 2028
Figure 3: 8MM, Total Prevalence of AD (%), Men and Women, Ages =60 Years, 2018
Figure 4: 8MM, Total Prevalence of MCI, Men and Women, Ages =60 Years, 2018
Figure 5: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of AD Based on the DSM-IV and Clinical Criteria
Figure 6: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of MCI
Figure 7: 8MM, Sources Used to Forecast the Total Prevalent Cases of AD by Severity
Figure 8: 8MM, Total Prevalent Cases of AD, Both Sexes, Ages =60 Years
Figure 9: 8MM, Total Prevalent Cases of AD, by Sex, Ages =60 Years, N, 2018
Figure 10: 8MM, Total Prevalent Cases of AD by Age, Both Sexes, N, 2018
Figure 11: 8MM, Total Prevalent Cases of AD by Severity, Both Sexes, Ages =60 Years, N, 2018
Figure 12: 8MM, Diagnosed Prevalent Cases of AD, Both Sexes, Ages =60 Years, N, 2018
Figure 13: 8MM, Diagnosed Prevalent Cases of AD, by Sex, Ages =60 Years, N, 2018
Figure 14: 8MM, Diagnosed Prevalent Cases of AD by Age, Both Sexes, N, 2018
Figure 15: 8MM, Diagnosed Prevalent Cases of AD by Severity, Both Sexes, Ages =60 Years, N, 2018
Figure 16: 8MM, Total Prevalent Cases of MCI, Both Sexes, Ages =60 Years
Figure 17: 8MM, Total Prevalent Cases of MCI, by Sex, Ages =60 Years, N, 2018
Figure 18: 8MM, Total Prevalent Cases of MCI by Age, Both Sexes, N, 2018
Figure 19: 8MM, Diagnosed Prevalent Cases of MCI, Both Sexes, Ages =60 Years
Figure 20: 8MM, Diagnosed Prevalent Cases of MCI, by Sex, Ages =60 Years, N, 2018
Figure 21: 8MM, Diagnosed Prevalent Cases of MCI by Age, Both Sexes, N, 2018

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3829EUR$3,995USD£3,190GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7657EUR$7,990USD£6,380GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€11486EUR$11,985USD£9,571GBP

Table of Contents

Related Topics

Related Reports

Alzheimer's Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

Alzheimer's Drugs Market Report by Drug Class, Drug Type, Distribution Channel, Region and Company Analysis 2024-2032

Agitation in Alzheimer's Disease - Market Insight, Epidemiology and Market Forecast - 2034

Alzheimer's Disease - Pipeline Insights, 2024

Global Alzheimer's Drugs Market Report by Drug Class, Distribution Channel, and Region 2024-2032